Endothelin-1 as a Potential Trigger of Migraine Aura

Migraine With Aura Clinical Trial

Official title:

Investigations of the Endogenous Vasoconstrictor and Neuromodulator Peptide Endothelin-1 as a Potential Trigger of Migraine Aura

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02906085
• Other study ID #: H-16022143
• Status: Active, not recruiting
• Phase: N/A
• Start date: October 2016
• Est. completion date: December 2019

Study information

• Verified date: December 2019
• Source: Glostrup University Hospital, Copenhagen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

One third of migraine patients experience aura, i.e. dramatic, transient neurological symptoms, most often in the form of visual disturbances, that usually appear before the onset of migraine headache. The likely underlying mechanism of aura is known as cortical spreading depression, a wave of changes in electrical activity that slowly spreads in the outermost layer of the brain. It is currently not known what causes the aura to initiate in patients or what the relationship is between aura and migraine headache, e.g. if treatment targeted at aura mechanisms will prevent subsequent headache. Due to the short-lasting and unpredictable nature of aura, the only possible approach for systematic investigations is to experimentally trigger aura, but currently no method for aura-triggering is available.

The overall goal of the proposed project is to reveal the earliest mechanisms of the migraine attack by investigating the initiating factors of aura in the migraine brain.

Current animal evidence indicates that infusion of endothelin-1 (ET-1), a naturally occurring signaling molecule released from blood vessels, is safe and very likely to trigger migraine aura in patients.

In this project the investigators aim to study the effects of ET-1 on the human brain, to investigate aura-inducing effects of ET-1 in patients and to develop a safe and reliable method for the experimental induction of migraine aura using ET-1.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 60
• Est. completion date: December 2019
• Est. primary completion date: May 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Age between 18 and 40 years

• Diagnosis of migraine with typical aura (patient group only)

• Attacks of migraine with aura at least once per month on average (patient group only)

• No history or family history of migraine (healthy subject group only)

• Use of safe contraception (women of fertile age only)

Exclusion Criteria:

• Tension-type headache more than one day per month on average

• Any other primary headache disorder

• Daily intake of medication

• Daily smoking during the past 5 years

• Pregnant or breastfeeding women

• Hypertension on the experimental day (systolic BP>150 mmHg or diastolic BP> 100 mmHg)

• History of any cardiovascular disease including cerebrovascular disease

• History of diabetes or hypercholesterolemia

• ECG changes suggestive of ischemia

• Contraindications of MRI

Related Conditions & MeSH terms

• Migraine Disorders
• Migraine with Aura

Intervention

Drug:
• Endothelin-1

• Placebo
Isotonic saline

Locations

Country	Name	City	State
Denmark	Danish Headache Center	Glostrup

Sponsors (1)

Lead Sponsor	Collaborator
Glostrup University Hospital, Copenhagen

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrence of migraine aura		0-24 hours
Secondary	Cerebral vasoconstriction: MR angiography	Time of flight arteriography using 3 tesla MRI (healthy subjects). Arterial diameters and circumferences (mm) will be measured from the resulting angiography images. This type of investigation will be carried out in healthy subjects only.	0-30
Secondary	Change in cerebral blood flow: Phase contrast mapping	Cerebral blood flow (perfusion, ml/100 g/min) measured before and after intervention using MRI phase contrast mapping (measure of global brain perfusion). This type of investigation will be carried out in healthy subjects only.	0-30 minutes
Secondary	Change in cerebral blood flow: Arterial spin labeling	Regional cerebral blood flow (perfusion, ml/100g/min) measured before and after intervention using MRI pseudo-continous arterial spin labelling at 3 tesla. This type of investigation will be carried out in healthy subjects only.	0-30 minutes